Skip to main content
. 2021 Dec 13;28(5):993–1003. doi: 10.1158/1078-0432.CCR-21-2498

Figure 5.

Figure 5. Pharmacodynamic biomarker analysis showing that ipatasertib treatment leads to downregulation of AKT and mTORC1 activities. A, Pharmacodynamic biomarker analysis showing the endpoints with differential expressions at C1D8 compared with its baseline levels in the PBO+PAC arm, IPAT+PAC arm, and the difference between the two arms. B, Downregulation of S6RP 235/236, S6RP S240/244, PRAS40 T246, and p70S6K S371 levels from baseline to C1D8 in the IPAT+PAC arm. C, Upregulation of AKT T308 and AKT S473 levels from baseline to C1D8 in the IPAT+PAC arm. D, The changes in phosphoprotein markers are more pronounced among the PIK3CA/AKT1/PTEN-altered (NGS) and PTEN-low (IHC) subgroups. E, The changes in phosphoprotein markers are more pronounced among responders (CR or PR) compared with nonresponders (PD or SD). Adj., adjusted; PD, progressive disease; SD, stable disease.

Pharmacodynamic biomarker analysis showing that ipatasertib treatment leads to downregulation of AKT and mTORC1 activities. A, Pharmacodynamic biomarker analysis showing the endpoints with differential expressions at C1D8 compared with its baseline levels in the PBO+PAC arm, IPAT+PAC arm, and the difference between the two arms. B, Downregulation of S6RP 235/236, S6RP S240/244, PRAS40 T246, and p70S6K S371 levels from baseline to C1D8 in the IPAT+PAC arm. C, Upregulation of AKT T308 and AKT S473 levels from baseline to C1D8 in the IPAT+PAC arm. D, The changes in phosphoprotein markers are more pronounced among the PIK3CA/AKT1/PTEN-altered (NGS) and PTEN-low (IHC) subgroups. E, The changes in phosphoprotein markers are more pronounced among responders (CR or PR) compared with nonresponders (PD or SD). Adj., adjusted; PD, progressive disease; SD, stable disease.